Funding
SAKK, Cancer
CANCER
This study was supported by the Swiss Group for Clinical Cancer Research (SAKK), the LOA IV funds, managed by curafutura, santésuisse and pharmaSuisse, and a grant from Krebsliga Schweiz and Swiss State Secretariat of Education, Research and Innovation (SERI). TZ, TP, SS, SA, UN, GR, JG, ZM, SH, AR, CR, CD: nothing to disclose. UM reports honoraria and travel support Celgene/BMS. EL reports consultancy for Celgene/BMS.